Connect your AI

Prime Medicine PRME Lessee Operating Lease Liability Payments Due

Lessee Operating Lease Liability Payments Due at other companies

Immix Biopharma, Inc.IMMX

——

PrecigenPGEN

——

Other financials

Income statement

Revenue$838.0K-61.6%

Operating income-$50.7M+3.3%

Net income-$49.1M+5.3%

EPS (diluted)-$0.28+30.0%

Balance sheet

Cash & equivalents$77.8M-26.6%

Total debt$114.5M-5.5%

Total equity$76.7M-28.3%

Total assets$294.7M-10.2%

Cash flow

Operating cash flow-$42.7M+12.6%

CapEx$214.0K-91.2%

Free cash flow-$42.9M+16.3%

Valuation

Market cap$574.36M+111%

Enterprise value$611.08M+113%

P/S124×+6.3×

Profitability

Operating margin-4,498.1%-1,134pp

Net margin-4,342.4%-1,099pp

FCF margin-3,607.4%—

Returns & leverage

Return on equity-216.1%+1,519pp

Debt / equity1.5×+0.4×

Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's lessee operating lease liability payments due.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Prime Medicine's lessee operating lease liability payments due?: Prime Medicine (PRME) reported lessee operating lease liability payments due of $179.08M in Q1 2026.
How has Prime Medicine's lessee operating lease liability payments due changed year-over-year?: Prime Medicine's lessee operating lease liability payments due decreased by 10.6% year-over-year, from $200.29M to $179.08M.